Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

Katherine S. Yang; Hyungsoon Im; Seonki Hong; Ilaria Pergolini; Andres Fernandez Del Castillo; Rui Wang; Susan Clardy; Chen Han Huang; Craig Pille; Soldano Ferrone; Robert Yang; Cesar M. Castro; Hakho Lee; Carlos Fernandez Del Castillo; Ralph Weissleder

doi:10.1126/scitranslmed.aal3226

Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

Katherine S. Yang, Hyungsoon Im, Seonki Hong, Ilaria Pergolini, Andres Fernandez Del Castillo, Rui Wang, Susan Clardy, Chen Han Huang, Craig Pille, Soldano Ferrone, Robert Yang, Cesar M. Castro, Hakho Lee, Carlos Fernandez Del Castillo, Ralph Weissleder

研究成果: 雜誌貢獻 › 期刊論文 › 同行評審

204 引文斯高帕斯（Scopus）

摘要

Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDAC^EV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDAC^EV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDAC^EV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDAC^EV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.

原文	???core.languages.en_GB???
期刊	Science Translational Medicine
卷	9
發行號	391
DOIs	https://doi.org/10.1126/scitranslmed.aal3226
出版狀態	已出版 - 24 5月 2017

存取文件

10.1126/scitranslmed.aal3226

引用此

Yang, K. S., Im, H., Hong, S., Pergolini, I., Del Castillo, A. F., Wang, R., Clardy, S., Huang, C. H., Pille, C., Ferrone, S., Yang, R., Castro, C. M., Lee, H., Del Castillo, C. F., & Weissleder, R. (2017). Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Science Translational Medicine, 9(391). https://doi.org/10.1126/scitranslmed.aal3226

@article{47cb60ee368e410199521aeb69e6790c,

title = "Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.",

author = "Yang, {Katherine S.} and Hyungsoon Im and Seonki Hong and Ilaria Pergolini and {Del Castillo}, {Andres Fernandez} and Rui Wang and Susan Clardy and Huang, {Chen Han} and Craig Pille and Soldano Ferrone and Robert Yang and Castro, {Cesar M.} and Hakho Lee and {Del Castillo}, {Carlos Fernandez} and Ralph Weissleder",

note = "Publisher Copyright: {\textcopyright} The Authors, some rights reserved;.",

year = "2017",

month = may,

day = "24",

doi = "10.1126/scitranslmed.aal3226",

language = "???core.languages.en_GB???",

volume = "9",

journal = "Science Translational Medicine",

issn = "1946-6234",

number = "391",

}

TY - JOUR

T1 - Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

AU - Yang, Katherine S.

AU - Im, Hyungsoon

AU - Hong, Seonki

AU - Pergolini, Ilaria

AU - Del Castillo, Andres Fernandez

AU - Wang, Rui

AU - Clardy, Susan

AU - Huang, Chen Han

AU - Pille, Craig

AU - Ferrone, Soldano

AU - Yang, Robert

AU - Castro, Cesar M.

AU - Lee, Hakho

AU - Del Castillo, Carlos Fernandez

AU - Weissleder, Ralph

PY - 2017/5/24

Y1 - 2017/5/24

N2 - Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.

AB - Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process. Clinical workup through imaging and tissue biopsies is often complex and expensive due to a paucity of reliable biomarkers. We used an advanced multiplexed plasmonic assay to analyze circulating tumor-derived extracellular vesicles (tEVs) in more than 100 clinical populations. Using EV-based protein marker profiling, we identified a signature of five markers (PDACEV signature) for PDAC detection. In our prospective cohort, the accuracy for the PDACEV signature was 84% [95% confidence interval (CI), 69 to 93%] but only 63 to 72% for single-marker screening. One of the best markers, GPC1 alone, had a sensitivity of 82% (CI, 60 to 95%) and a specificity of 52% (CI, 30 to 74%), whereas the PDACEV signature showed a sensitivity of 86% (CI, 65 to 97%) and a specificity of 81% (CI, 58 to 95%). The PDACEV signature of tEVs offered higher sensitivity, specificity, and accuracy than the existing serum marker (CA 19-9) or single-tEV marker analyses. This approach should improve the diagnosis of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=85020031290&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aal3226

DO - 10.1126/scitranslmed.aal3226

M3 - 期刊論文

C2 - 28539469

AN - SCOPUS:85020031290

SN - 1946-6234

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 391

ER -

Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy

摘要

存取文件

指紋

引用此